Standout Papers

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/indepe... 2014 2026 2018 2022 439
  1. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine (2014)
    Lawrence M. Gelbert, Shufen Cai et al. Investigational New Drugs

Immediate Impact

14 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Computational approaches streamlining drug discovery
2023 StandoutNature
2 intermediate papers

Works of Alfonso de Dios being referenced

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
2017
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014 Standout

Author Peers

Author Last Decade Papers Cites
Alfonso de Dios 930 438 990 490 37 1.8k
Carolyn Discafani 563 864 1391 1393 30 3.0k
Jon Curwen 622 487 995 1465 31 2.7k
William L. Elliott 834 538 1301 948 43 2.3k
Blake Lee Neubauer 1005 221 794 1443 55 2.9k
Gerd Bader 956 266 831 1436 50 2.6k
Anne T. Truesdale 493 398 953 1045 16 2.3k
Yiqun Li 454 238 668 857 24 1.7k
Laurent Hennequin 493 769 961 1465 51 2.7k
Jinee Rizzo 639 112 1179 647 26 1.8k
Andrea Cavazzoni 976 406 1186 1111 75 2.5k

All Works

Loading papers...

Rankless by CCL
2026